Newcleo Secures EUR75 Million Funding Round with Cementir Among Investors
HQ: FR
Founded: 2021
Venture – Series Unknown
Sector: Clean Energy
Investment Raised: EUR 75m €
Valuation Remains Undisclosed
Investors: The round welcomed new investors such as Cementir Holding, Danieli & C, and Orion Valves, alongside existing shareholders including Kairos, Indaco Ventures, Azimut Investments, the CERN pension fund, and Walter Tosto. Among the recent additions is NextChem, a MAIRE subsidiary, which joined the capital following its joint venture with Newcleo.
Kraken Technologies Raises $1 Billion in First Standalone Round at $8.65 Billion Valuation
HQ: UK
Founded: 2019
Venture – Series Unknown
Sector: Artificial Intelligence, Energy
Investment Raised: USD 1b €
USD 8.65b
Valuation
Investors: The investment round was led by D1 Capital Partners, with participation from Fidelity International, Ontario Teachers’ Pension Plan Board, and Durable Capital Partners.
Renewco Power Secures £29 Million to Accelerate Utility-Scale Renewables Across the UK and Europe
HQ: UK
Founded: 2021
Venture – Series Unknown
Sector: Renewable Energy
Investment Raised: GBP 29m €
Valuation Remains Undisclosed
Investors: The investment round was led by a £20 million commitment from Scottish National Investment Bank, alongside a further £9 million from existing shareholder SSE plc
HoloSolis Secures €220M to Build One of Europe’s Largest Solar Manufacturing Plants
HQ: FR
Founded: 2023
Venture – Series Unknown
Sector: Renewable Energy
Investment Raised: EUR 220m €
Valuation Remains Undisclosed
Investors: Backed by Calés Technologie and Forming, and a solid base of long-standing investors including InnoEnergy, TSE, Groupe IDEC, Armor Group, and Heraeus
Enterome raises $19 million to fund clinical development of its OncoMimics™ immunotherapy to treat Follicular Lymphoma
HQ: FR
Founded: 2012
Venture – Series Unknown
Sector: Biotechnology
Investment Raised: USD 19m €
Valuation Remains Undisclosed
Investors: Institute for Follicular Lymphoma Innovation, Lundbeckfonden Ventures, Primo Capital, Seventure Partners, SymBiosis, The Leukemia & Lymphoma Society’s Therapy Acceleration Program